Trials / Completed
CompletedNCT03067441
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,462 (actual)
- Sponsor
- Esperion Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bempedoic acid | bempedoic acid 180 mg tablets taken orally, once per day. |
Timeline
- Start date
- 2017-02-03
- Primary completion
- 2019-11-05
- Completion
- 2019-11-05
- First posted
- 2017-03-01
- Last updated
- 2021-03-01
- Results posted
- 2020-12-22
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03067441. Inclusion in this directory is not an endorsement.